Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
doi: 10.1016/0014-5793(82)80708-4 14 BatailleDGespachCCoudrayAMRosselinG
The deal with Eli Lilly and Novo Nordisk is set to expand Medicare coverage of Zepbound and Wegovy, two GLP-1 receptor agonist medications
J Clin Invest 117:21552163 Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function
demonstrated that the GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant Apoe/Irs2+/ mice by promoting macrophage polarization towards an anti-inflammatory M2 phenotype, which was associated with enhanced plaque stability (i.e., thicker fibrous caps, fewer necrotic cores, and decreased inflammatory infiltrates)
US$ 20.56
US$ 23.87
US$ 28.89
